---
schema_version: "secwatch.filing_event.v1"
accession: "0001906324-26-000013"
form_type: "8-K"
ticker: "QDEL"
cik: "0001906324"
company_name: "QuidelOrtho Corp"
filed_at: "2026-04-15T23:59:59+00:00"
generated_at: "2026-05-15T06:10:46.924415+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# QuidelOrtho prelim Q1 rev $615-620M; weaker respiratory season, China headwinds

## Summary
- Prelim Q1 2026 revenue of $615-$620M; U.S. flu-like illness visits down ~30% YoY.
- China distributor sales slow on proposed NHSA reimbursement cuts; EMEA orders delayed by Middle East conflict.
- Q1 2026 free cash flow guided to negative $(65)-$(70)M; positive full-year still expected.
- Low end of FY 2026 guidance remains achievable; full discussion on May 5 earnings call.
- Core business (>70% of total rev) remains strong; cost actions underway to drive 2026 performance.

## SEC filing metadata
- accession: 0001906324-26-000013
- form_type: 8-K
- ticker: QDEL
- cik: 0001906324
- company_name: QuidelOrtho Corp
- filed_at: 2026-04-15T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1906324/000190632426000013/0001906324-26-000013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1906324/000190632426000013/qdel-20260415.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001906324-26-000013
- JSON: https://secwatch.observer/filing/0001906324-26-000013.json
- Plain text: https://secwatch.observer/filing/0001906324-26-000013.txt

## Key facts
- Earnings Releases
  QuidelOrtho Corp reported first quarter of 2026, ended March 29, 2026 results: revenue $615-$620 million. Guidance reaffirmed.
  - Period: first quarter of 2026, ended March 29, 2026
  - Revenue: $615-$620 million
  - Guidance: reaffirmed
  - Result: preliminary results
  source text: on Tuesday, May 5, 2026, after the market closes. Preliminary Unaudited First Quarter 2026 Revenue The Company currently expects preliminary unaudited revenue, as reported, of $615-$620 million for the first quarter of 2026. This preliminary unaudited revenue was primarily driven by a weaker respiratory season, with U.S. Influenza-like Illness visits down
  evidence_url: https://www.sec.gov/Archives/edgar/data/1906324/000190632426000013/0001906324-26-000013-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.